Quinidine sulfate    (DrugBank: Quinidine, Sulfate)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎4

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-002178-22-GB
(EUCTR)
27/04/201229/03/2012A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Central Neuropathic Pain in Multiple Sclerosis
MedDRA version: 14.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Avanir Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
2EUCTR2011-002178-22-PL
(EUCTR)
20/03/201225/11/2011A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Central Neuropathic Pain in Multiple Sclerosis
MedDRA version: 15.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Avanir Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
3EUCTR2011-002178-22-CZ
(EUCTR)
08/02/201202/11/2011A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Central Neuropathic Pain in Multiple Sclerosis
MedDRA version: 14.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Avanir Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
4NCT00573443
(ClinicalTrials.gov)
December 200713/12/2007Safety and Efficacy of AVP-923 in PBA Patients With ALS or MSA Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)Pseudobulbar Affect (PBA)Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: PlaceboAvanir PharmaceuticalsINC ResearchCompleted18 Years80 YearsAll326Phase 3United States;Argentina;Brazil